mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis

This study aims to evaluate the role of the circulating epigenetic biomarker mSEPT9 in predicting the risk of hepatocellular carcinoma (HCC) in patients with cirrhosis. HCC is a primary liver cancer that frequently develops in individuals with cirrhosis, and early detection is critical for improving outcomes. This research involves 400 patients with cirrhosis who will be followed every six months for up to 60 months. During these visits, blood samples will be collected to analyze mSEPT9 levels. By identifying changes in this biomarker, the study seeks to improve early diagnosis and personalize surveillance strategies, potentially enhancing patient survival and quality of life.

NCT Number	NCT06778317
Lead Sponsor	Central Hospital, Nancy, France Collaborators: New Day Diagnostics
Conditions	Hepatocellular Carcinoma (HCC), Cirrhosis, Risk Prediction for Liver Cancer, Epigenomics
Enrollment	400 participants
Start Date	2025-06-03
Primary Completion	2033-06-03 (estimated)
Study Completion	2033-06-03 (estimated)
Updated on ClinicalTrials.gov	2026-06-10